Abstract | PURPOSE: METHODS: RESULTS: DFS was not affected by use of preoperative chemotherapy versus immediate surgery, by use of limb-sparing surgery versus amputation, age, sex, or dose intensity of chemotherapy. DFS did correlate with serum lactate dehydrogenase (LDH), alkaline phosphatase, primary tumor site, race, and histologic response to preoperative chemotherapy. There was no difference in DFS for patients with a poor histologic response who did or did not receive cisplatin, although patients who did receive cisplatin had a longer time to relapse. The 5-year DFS was 76% for patients aged less than or equal to 21 years who had extremity primary tumor and were treated with the T10 protocol. CONCLUSIONS: Intensive chemotherapy can achieve DFS for a high proportion of patients with OS. Although it is a powerful predictor of DFS, histologic response to preoperative chemotherapy cannot be assessed at diagnosis. We have not shown an ability to salvage patients with an unfavorable response. We need to increase the proportion of patients with a favorable response, identify the patients who will have an unfavorable response, and develop novel treatments to salvage poor responders.
|
Authors | P A Meyers, G Heller, J Healey, A Huvos, J Lane, R Marcove, A Applewhite, V Vlamis, G Rosen |
Journal | Journal of clinical oncology : official journal of the American Society of Clinical Oncology
(J Clin Oncol)
Vol. 10
Issue 1
Pg. 5-15
(Jan 1992)
ISSN: 0732-183X [Print] United States |
PMID | 1370176
(Publication Type: Journal Article)
|
Chemical References |
- Biomarkers, Tumor
- Bleomycin
- Dactinomycin
- Doxorubicin
- Cyclophosphamide
- Cisplatin
- Methotrexate
|
Topics |
- Adolescent
- Adult
- Analysis of Variance
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Biomarkers, Tumor
(blood)
- Bleomycin
(administration & dosage)
- Bone Neoplasms
(blood, drug therapy, surgery)
- Child
- Cisplatin
(administration & dosage)
- Combined Modality Therapy
- Cyclophosphamide
(administration & dosage)
- Dactinomycin
(administration & dosage)
- Doxorubicin
(administration & dosage)
- Female
- Humans
- Male
- Methotrexate
(administration & dosage)
- Osteosarcoma
(blood, drug therapy, surgery)
- Proportional Hazards Models
- Risk Factors
- Survival Analysis
|